Emergent Product Development Gaithersburg Inc.

University of Iowa Research Foundation

University of Rochester

Antex Biologics, Inc.

Ithaca College

Emergent Product Development of Gaithersburg, Inc.

Kenneth D Tucker

Laura Plosila

Ulrich F Tillman

James Philip Pearson

Barbara H Iglewski

Everett P Greenberg

Luciano Passador

Anatol Eberhard

Kendall M Gray

Ulrich F Tillmann

The invention discloses theouter membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding OMP106 polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses toandOMP106 polypeptides and OMP106-derived polypeptides in animals.

[object Object]

The invention discloses theouter membrane protein polypeptide and polypeptides derived therefrom (collectively 'OMP21'), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response toand OMP21 in an animal, preferably a human, methods of treating and methods of diagnosinginfections in an animal, preferably a human, and kits therefor.

The invention discloses theouter membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses toandOMP106 polypeptides and OMP106-derived polypeptides in animals.

Autoinducer molecules, e.g., N-(3-oxododecanoyl)homoserine lactone, forare described. The molecules regulate gene expression in the bacterium. Therapeutic compositions and therapeutic methods involving analogs and/or inhibitors of the autoinducer molecules also are described. The molecules are useful for treating or preventing infection by

Autoinducer molecule

The invention discloses the outer membrane protein polypeptide and polypeptides derived therefrom (collectively &ldquo;OMP21&rdquo;), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.

Moraxella catarrhalis protein, gene sequence and uses thereof

The invention discloses the,outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to,and,OMP106 polypeptides and OMP106-derived polypeptides in animals.

Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof

Autoinducer molecules, e.g., N-(3-oxododecanoyl)homoserine lactone, for Pseudomonas aeruginosa are described. The molecules regulate gene expression in the bacterium. Therapeutic compositions and therapeutic methods involving analogs and/or inhibitors of the autoinducer molecules also are described. The molecules are useful for treating or preventing infection by Pseudomonas aeruginosa.

Growing community of inventors

Germantown, MD, United States of America

Kenneth D Tucker